Mr. McDonough brings over 16 years of experience in diagnostic healthcare and life sciences to CombiMatrix. Led by his passion for patient care, he has spent his career growing early stage and emerging cancer diagnostics, molecular diagnostics and commercial laboratory organizations.

In August 2012, Mr. McDonough joined CombiMatrix as Chief Commercial Officer. His efforts to optimize the commercial aspects of CombiMatrix and his focus on prenatal testing have made an immediate impact on the Company’s long-term strategy and financial success.  Mr. McDonough came to CombiMatrix from Pathwork Diagnostics where he was Vice President of Sales and Service.  His business acumen was instrumental in driving all phases of their commercial efforts, including sales, reimbursement strategies and market creation of novel diagnostics that fulfilled a critical, yet unmet need for patients with metastatic disease.    

Preceding Pathwork Diagnostics, Mr. McDonough held positions of increasing responsibility at US LABS, ultimately assuming the role of Vice President of Sales. He also served in an executive capacity at Dianon and Laboratory Corporation of America (post acquisition). His contributions as a field sales resource and sales leader from 2002-2004 were instrumental in the growth of US LABS from $17M to $75M, resulting in the successful acquisition by Laboratory Corporation of America in early 2005.  Mr. McDonough was with EMC Corporation and Ventana Medical Systems previous to US LABS.

Prior to entering the healthcare industry, Mr. McDonough was a ranking officer in the United States Navy for six years where he served as Navigator of the USS FLETCHER (DD 992).

Mr. McDonough received a Bachelor’s Degree in Finance from Miami University-Ohio.

Scott R. Burell has served as our Chief Financial Officer since November 2006. Previously, he served as Vice President of Finance from November 2001 through November 2006, and as the Company's Controller from February 2000 through November 2001. From May 1999 to February 2001, Mr. Burell served as the Controller for Network Commerce, Inc., a publicly traded technology and infrastructure company located in Seattle. Prior to May 1999, Mr. Burell spent 9 years with Arthur Andersen's Audit and Business Advisory practice in Seattle. Mr. Burell is a certified public accountant in the state of Washington (currently inactive) and holds B.S. degrees in Accounting and Business Finance from Central Washington University. Mr. Burell is a member of the American Institute and Washington Society of Certified Public Accountants.

Richard D. Hockett, Jr., M.D. has served as our Chief Medical Officer since April 30, 2012. Prior to joining us, Dr. Hockett was the Chief Medical Officer from March 2009 to April 2012 at Affymetrix, Inc., a genomic analysis tools company, where his responsibilities included applied genomics, new technology development, and regulatory affairs. From November 2008 to March 2009, Dr. Hockett was an independent consultant for Affymetrix. From 1999 to November 2008, Dr. Hockett was a Medical Fellow II, Group Leader for Genomic Medicine at Eli Lilly and Company, a pharmaceutical company. Dr. Hockett started his career as an Academic Pathologist in the Department of Pathology at the University of Alabama at Birmingham, where he oversaw the Clinical Immunology and Molecular Diagnostic Laboratories. Dr. Hockett is a board certified Clinical Pathologist, received his M.D. degree from the University of Minnesota and did his residency in Clinical Pathology at Washington University, St. Louis.